“Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.”, Mol Ther Methods Clin Dev, vol. 3, p. 16061, 2016.
, “Cryopreservation-related loss of antigen-specific IFNγ producing CD4 T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.”, Vaccine, vol. 35, no. 15, pp. 1898-1906, 2017.
, “First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.”, J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
, “In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”, PLoS One, vol. 6, no. 5, p. e19252, 2011.
, “A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”, PLoS One, vol. 7, no. 8, p. e41936, 2012.
, “Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.”, AIDS Res Hum Retroviruses, vol. 21, no. 1, pp. 68-81, 2005.
, “Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.”, Lancet Infect Dis, vol. 22, no. 8, pp. 1210-1220, 2022.
, “Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”, PLoS One, vol. 5, no. 9, p. e12873, 2010.
, “Standardization and validation issues of the ELISPOT assay.”, Methods Mol Biol, vol. 302, pp. 51-86, 2005.
,